Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of enzyme activity is not practical in many clinical centres, we have investigated the use of DNA mutation...

Full description

Bibliographic Details
Main Authors: Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F. J., Cassidy, J., McLeod, H. L.
Format: Online
Language:English
Published: Nature Publishing Group 1998
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151292/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151292/

Similar Items